Tyck till om SwePub Sök
här!
Sökning: onr:"swepub:oai:DiVA.org:umu-14004" >
Similar efficacy fo...
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
-
Ejlertsen, Bent (författare)
-
Mouridsen, Henning T (författare)
-
Jensen, Maj-Britt (författare)
-
visa fler...
-
- Bengtsson, Nils-Olof (författare)
- Umeå universitet,Onkologi
-
Bergh, Jonas (författare)
-
Cold, Soren (författare)
-
Edlund, Per (författare)
-
Ewertz, Marianne (författare)
-
de Graaf, Peter W (författare)
-
Kamby, Claus (författare)
-
Nielsen, Dorte L (författare)
-
visa färre...
-
(creator_code:org_t)
- American Society of Clinical Oncology (ASCO), 2006
- 2006
- Engelska.
-
Ingår i: J Clin Oncol. - : American Society of Clinical Oncology (ASCO). - 1527-7755. ; 24:31, s. 4956-4962
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- To compare the efficacy of ovarian ablation versus chemotherapy in early breast cancer patients with hormone receptor–positive disease. Patients and Methods We conducted an open, randomized, multicenter trial including premenopausal breast cancer patients with hormone receptor–positive tumors and either axillary lymph node metastases or tumors with a size of 5 cm or more. Patients were randomly assigned to ovarian ablation by irradiation or to nine courses of chemotherapy with intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) administered every 3 weeks. Results Between 1990 and May 1998, 762 patients were randomly assigned, and the present analysis is based on 358 first events. After a median follow-up time of 8.5 years, the unadjusted hazard ratio for disease-free survival in the ovarian ablation group compared with the CMF group was 0.99 (95% CI, 0.81 to 1.22). After a median follow-up time of 10.5 years, overall survival (OS) was similar in the two groups, with a hazard ratio of 1.11 (95% CI, 0.88 to 1.42) for the ovarian ablation group compared with the CMF group. Conclusion In this study, ablation of ovarian function in premenopausal women with hormone receptor–positive breast cancer had a similar effect to CMF on disease-free and OS. No significant interactions were demonstrated between treatment modality and hormone receptor content, age, or any of the well-known prognostic factors.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ejlertsen, Bent
-
Mouridsen, Henni ...
-
Jensen, Maj-Brit ...
-
Bengtsson, Nils- ...
-
Bergh, Jonas
-
Cold, Soren
-
visa fler...
-
Edlund, Per
-
Ewertz, Marianne
-
de Graaf, Peter ...
-
Kamby, Claus
-
Nielsen, Dorte L
-
visa färre...
- Artiklar i publikationen
-
J Clin Oncol
-
Journal of Clini ...
- Av lärosätet
-
Umeå universitet